|
Abbreviated name: BTLA
Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272
Compound class:
Endogenous peptide in human, mouse or rat
Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [3-6] by enabling tumour immune evasion. Immunotherapeutics that block the BTLA-HVEM checkpoint offer potential as anti-tumour agents [7-8]. In the setting of inflammatory diseases anti-BTLA antibodies can induce inhibitory signalling and T cell activation, and reduce cytokine secretion [1].
There is information confirming two anti-BTLA monoclonals that were progressed to clinical development: HFB200603 (HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] and ANB032 (AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1].
Species: Human
|
| Natural/Endogenous Targets | ||
|
||
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Other ligands which bind to or alter the activity of this ligand | ||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
